← Product Code [DHN](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DHN) · K984400

# LIQUICHEK ANA CONTROL, SPECKLED PATTERN, MODEL 202 (K984400)

_Bio-Rad · DHN · Dec 18, 1998 · Immunology · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DHN/K984400

## Device Facts

- **Applicant:** Bio-Rad
- **Product Code:** [DHN](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DHN.md)
- **Decision Date:** Dec 18, 1998
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 866.5100
- **Device Class:** Class 2
- **Review Panel:** Immunology

## Indications for Use

Liquichek ANA Control, Speckled Pattern is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing of antinuclear antibodies (ANA).

## Device Story

Liquichek ANA Control, Speckled Pattern is an in vitro diagnostic quality control product used in clinical laboratories. It consists of human serum supplemented with preservatives (0.1% sodium azide) and stabilizers, provided in a liquid format. The device serves as a control for monitoring the accuracy and precision of indirect immunofluorescent assays designed to detect antinuclear antibodies. Laboratory personnel use the control alongside patient samples during routine testing. By comparing the observed results of the control against expected values, clinicians verify the performance of the immunofluorescent test system. This process ensures the reliability of patient test results, aiding in the accurate diagnosis and management of autoimmune conditions associated with antinuclear antibodies.

## Clinical Evidence

No clinical data provided; bench testing only.

## Technological Characteristics

Human serum-based quality control; contains 0.1% sodium azide preservative. Provided in liquid form. Storage at 2-8°C. Open-vial stability of 30 days at 2-8°C. Designed for monitoring ANA (Speckled Pattern) indirect immunofluorescent assays.

## Regulatory Identification

An antinuclear antibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoimmune antibodies in serum, other body fluids, and tissues that react with cellular nuclear constituents (molecules present in the nucleus of a cell, such as ribonucleic acid, deoxyribonucleic acid, or nuclear proteins). The measurements aid in the diagnosis of systemic lupus erythematosus (a multisystem autoimmune disease in which antibodies attack the victim's own tissues), hepatitis (a liver disease), rheumatoid arthritis, Sjögren's syndrome (arthritis with inflammation of the eye, eyelid, and salivary glands), and systemic sclerosis (chronic hardening and shrinking of many body tissues).

## Predicate Devices

- Kallestad Quantafluor Autoantibody Positive Control ([K813592](/device/K813592.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}------------------------------------------------

DEC 1 8 1998

Image /page/0/Picture/14 description: The image shows the logo for BIO-RAD. The logo is in black and white, with the words "BIO" and "RAD" in large, bold letters. The plus sign is between the two words. The logo is surrounded by a black border. The date DEC 16 1986 is at the top of the image.

Bio-Rad Laboratories

California 92618-2011 Telephone: (949) 598-1200

# 510(k) Summary

Submitter Bio-Rad Laboratories 9500 Jeronimo Road Irvine, CA (949)598-1285 Fax (949)598-1555

Contact Person Elizabeth Platt

Date of Summary Preparation December 8, 1998

Device (Trade & Common Name) Liquichek ANA Control, Speckled Pattern

Classification Name Class II, 82DHN CFR 866.5100: Antinuclear Antibody, Indirect Immunofluorescent, Antigen, Control.

Devices to Which Substantial Equivalence is Claimed Kallestad Quantafluor Autoantibody Positive Control Sanofi Diagnostics Pasteur Chaska, Minnesota K813592

#### Statement of Intended Use

Liquichek ANA Control, Speckled Pattern is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing of antinuclear antibodies (ANA).

{1}------------------------------------------------

Image /page/1/Picture/0 description: The image shows the logo for BIO-RAD. The logo is in white text on a black background. The text is bold and sans-serif.

Bio-Rad Laboratories Diagnostics Group 9500 Jeronimo Road Irvine, California 92618-2017 Telephone: (949) 598-1200

## Description of the Device

Liquichek ANA Control, Speckled Pattern is prepared from human serum with added preservatives and stabilizers. This product is provided in liquid form for convenience. This product contains 0.1% sodium azide as a preservative.

## Statement of How Technological Characteristics Compare to Substantial Equivalent Device

A table is provided below comparing the similarities between the Bio-Rad Liquichek ANA Control, Speckled Pattern and the device to which substantial equivalence is claimed.

|                    | Kallestad Quantafluor Autoantibody Positive<br>Control                                                                                                                                     | Bio-Rad Liquichek<br>ANA Control, Speckled Pattern                                                                             |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Intended Use       | Autoantibody positive control for Kallestad<br>Quantafluor Fluorescent Autoantobody Test<br>with mouse kidney, mouse stomach/kidney,<br>Hep-2 cell line, or Crithidia luciliae substrates. | An unassayed quality control<br>serum for monitoring indirect<br>immunofluorescent testing of<br>antinuclear antibodies (ANA). |
| Form               | Lyophilized                                                                                                                                                                                | Liquid                                                                                                                         |
| Matrix             | Human Serum                                                                                                                                                                                | Human Serum                                                                                                                    |
| Levels             | Positive                                                                                                                                                                                   | Negative, Positive, High<br>Positive                                                                                           |
| Storage            | 2-8°C                                                                                                                                                                                      | 2-8°C                                                                                                                          |
| Analytes           | ANA (Centromere, SSA, SSB, Scl-70, Sm,<br>RNP, Spindle, Nucleolar)<br>AMA<br>ASMA<br>APCA<br>Anti-nDNA                                                                                     | ANA (Speckled Pattern)                                                                                                         |
| Open Vial<br>Claim | 6 weeks at 2-8°C<br>4 months at -20°C                                                                                                                                                      | 30 Days at 2-8°C                                                                                                               |

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features a stylized eagle with three overlapping profiles, symbolizing health, services, and people. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

DEC 1 8 1998

Elizabeth Platt Regulatory Affairs Supervisor Bio-Rad Laboratories 9500 Jeronimo Road Irvine, CA 92618

Re: K984400

Trade Name: Liquichek ANA Control, Speckled Pattern, Model 202 Regulatory Class: II Product Code: DHN Dated: December 8, 1998 Received: December 9, 1998

Dear Ms. Platt:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Ouality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{3}------------------------------------------------

#### Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"

Sincerely yours,

Steven Sutman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Page 1 of 1

510(k) Number: _______________________________________________________________________________________________________________________________________________________________ Device Name: Liquichek ANA Control, Speckled Pattern

Indications for Use:

Liquichek ANA Control, Speckled Pattern is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing of antinuclear antibodies (ANA).

## (PLEASE DO NOT WRITE BELOW THE LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

(Concurrence of CDRH, Office of Device Evaluation)

| (Division Sign-Off)                     |  |
|-----------------------------------------|--|
| Division of Clinical Laboratory Devices |  |
| 510(k) Number                           |  |

| Prescription Use |  | OR | Over-The Counter Use |  |
|------------------|--|----|----------------------|--|
|------------------|--|----|----------------------|--|

---

**Source:** [https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DHN/K984400](https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/DHN/K984400)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com